ResMed, Inc.

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 02:30:02 07/02/2026 am IST			5-day change	1st Jan Change
271.63 ^USD	+1.72%		+5.16%	+12.77%

06/02	Resmed Insider Sold Shares Worth $502,620, According to a Recent SEC Filing	MT
06/02	ResMed Chief Legal Officer Sells 50 Common Shares Of Firm	MT

ResMed CFO Sells Shares

Published on 11/04/2025 at 03:55 am IST

MT Newswires

Latest news about ResMed, Inc.

06/02	Resmed Insider Sold Shares Worth $502,620, According to a Recent SEC Filing	MT
06/02	ResMed Chief Legal Officer Sells 50 Common Shares Of Firm	MT
06/02	ResMed Director Sells 2,000 Shares	MT
06/02	ASX Biggest Gainers	MT
05/02	ASX Biggest Gainers	MT
04/02	Resmed Insider Sold Shares Worth $257,030, According to a Recent SEC Filing	MT
03/02	Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge	RE
02/02	America's New Gold Rush (and Why It Just Face-Planted)
02/02	Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73	MT
02/02	Analyst recommendations: Apple, Autodesk, Best Buy, Caterpillar, PayPal…
30/01	Sector Update: Health Care Stocks Fall Premarket Friday	MT
30/01	Sector Update: Health Care	MT
30/01	RBC Raises Price Target on ResMed to $314 From $311, Keeps Outperform Rating	MT
30/01	Wolfe Adjusts Price Target on ResMed to $230 From $225, Maintains Underperform Rating	MT
30/01	Wells Fargo Adjusts Price Target on ResMed to $270 From $265, Maintains Equalweight Rating	MT
30/01	KeyBanc Adjusts Price Target on ResMed to $302 From $299, Maintains Overweight Rating	MT
30/01	Stifel Adjusts Price Target on ResMed to $265 From $260, Maintains Hold Rating	MT
30/01	Jefferies Adjusts Price Target on ResMed to $290 From $285, Maintains Hold Rating	MT
30/01	Citigroup Adjusts Price Target on ResMed to $345 From $330, Maintains Buy Rating	MT
30/01	Baird Adjusts Price Target on ResMed to $281 From $275, Maintains Neutral Rating	MT
30/01	Piper Sandler Adjusts Price Target on ResMed to $275 From $270, Maintains Neutral Rating	MT
30/01	Top Premarket Gainers	MT
30/01	Malaysia, Singapore Finalizing 'Master Plan' for Investment Hub as Billions Pour In	DJ
30/01	ResMed Inc., Q2 2026 Earnings Call, Jan 29, 2026
30/01	ResMed Posts Higher Fiscal Q2 Non-GAAP Earnings, Revenue	MT

Mr. Brett A. Sandercock is a Chief Financial Officer at ResMed, Inc. and a Non-Executive Chairman at Osteopore Ltd. Mr. Sandercock was previously employed as a Manager-Financial Accounting & Group Reporting by Norton Co., a Principal by Norton Co., a Group Management Accountant by Healthcare of Australia Pty Ltd., a Principal by PricewaterhouseCoopers (Australia), and a Non-Executive Director by CAP-XX Ltd. He received his undergraduate degree from Macquarie University.

View full profile

Chart ResMed, Inc.

Duration

Period

RMD: Dynamic Chart

Company Profile

ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (51.8%); - masks (35.7%); - software as a service (12.5%): residential care management software solutions. At the end of June 2025, the group had 8 production sites located in the United States (3), Australia, China, Singapore, Malaysia and France. The United States accounts for 63.8% of net sales.

Employees

10,600

Sector

Advanced Medical Equipment & Technology

Calendar

23/04 - Q3 2026 Earnings Release (Projected)

More about the company